Office Location: Wohl Clinic Building, 5th Floor
660 S. Euclid Ave
Campus Box 8127
St. Louis, MO 63110
Office Phone: (314) 747-0099
Fax: (314) 747-3963
E-mail Address: firstname.lastname@example.org
My name is Victoria Adjovu and I was born in Huntsville, Alabama. At the age of 10 my family relocated to Ghana in West Africa. It was at this time that I developed an interest in medicine and realized that I wanted to become a doctor. I lived in Ghana for 8 years and returned to the United States for college at the University of Alabama in Huntsville (UAH). At UAH, I majored in biology and chemistry and also participated in research and community projects. After graduation from college, I was awarded a NIH research scholarship under Dr. Kimberly Blackwell at Duke University. My research project investigated the migration of epithelial cells under various antiestrogenic drugs. I subsequently went to medical school at Northwestern Medical School in Chicago, IL where I did further clinical research under Dr. Daniel Lee and Dr. Robert Bonow in cardiology. After medical school I did an internal medicine residency at Loyola Medical Center. After completion on residency, I worked in primary care for 2 years at Cape Girardeau, MO where I focused my clinical interest in endocrinology and obesity.
Outside of medicine, I enjoy spending time with my fiancé and 5 year old son. I also enjoy exercise, singing in church, travelling and community events such as mentorship and health related events. I also have a passion for medical missions.
I am excited about my move to St Louis and all that the city has to offer. So far, we have enjoyed the parks and great restaurants and looking forward to learning more about the city.
Despite improvements in medicines for glycemic control in patients with Type 1 diabetes, they still have a high risk for end-stage renal disease. There is evidence to suggest that moderately elevated serum uric acid is a strong, independent predictor of an increased risk of chronic kidney disease as well as increased rate of decline in kidney function. My research involves evaluating the efficacy of allopurinol, a urate lowering drug, as compared to placebo in reducing kidney function loss in Type 1 diabetics.
There continues to be poor glycemic control and treatment outcomes for patients with Type 2 diabetes. Poor weight control, medication non-adherence and intolerability contribute to suboptimal glycemic control. Glucagon-like peptide-1 (GLP-1) receptor agonists are currently subcutaneous injections that are being used to achieve glycemic control and weight reduction in patients with type 2 diabetes. My research involves comparing the Efficacy, Safety and Tolerability of ITCA 650 (a miniature subcutaneously placed osmotic pump delivering exenatide) to Sitagliptin as Add-on Therapy to Metformin in Patients with Type 2 Diabetes.